ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 757

Beneficial Role of Rapamycin in Experimental Autoimmune Myositis

Nicolas Prevel1, Yves Allenbach2, David Klatzman1, Benoit Salomon1 and Olivier Benveniste3, 1UPMC Université Paris 06, UMR 7211, Paris, France, 2Internal Medicine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, 3Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, polymyositis/dermatomyositis (PM/DM) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Classification, Treatment and Outcome in Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Idiopathic inflammatory myopathies are a heterogeneous group of different diseases, classified into four main categories: dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and sporadic inclusion body myositis. The treatment of polymyositis consists of corticosteroids frequently associated to other immunosuppressive drugs. The obligatory and often severe side effects of these drugs, which have to be taken for several months or years, prompted us to propose alternative treatments, which have to be tested first in experimental animal models. Rapamycin is a known potent immunomodulator with less side effects compared to other immunosuppressants (e.g. ciclosporin). Rapamycin has been used for a decade in transplant patients to prevent graft rejection. In vivo, rapamycin has been described to increase the percentage of regulatory T cells. Our objective was to Study the role of rapamycin in an experimental autoimmune myositis (EAM) model of polymyositis in mouse (Allenbach Y et al. Am J Pathol, 2009, 174, 989-998).

Methods: EAM is induced by 3 injections of myosin coupled with complete Freund’s adjuvant. Mice received rapamycin (1 mg or 3 mg/kg/day) during 25 days starting before myosin immunization (preventive treatment), or during 10 days following the last myosin immunization (curative treatment). Muscle strength and histology, composition of lymphocyte subpopulations, and KLF2 pathway, a transcription factor controlling lymphocyte homing, were studied. 

Results: Under preventive or curative treatment, an increase of muscle strength was observed with in parallel a decrease of muscle inflammation, both being well correlated (R2=-0.645, p<0.0001). Rapamycin induced a general decrease in frequency of effector T cells (lymphopenia in draining or non draining lymph nodes and spleen, harmoniously distributed between CD4+ and CD8+ T cells, but sparing B cells), and an increase in frequency of regulatory T cells (CD4+CD25+) in draining lymph nodes (rapamycin 3 mg/kg/day preventively treated mice compared to controls: 16.9±2.2% vs. 9.3±1.4%, p<0.001), which were mostly activated regulatory T cells (CD62LlowCD44high: 58.1±5.78% vs. 33.1±7%, treated vs. untreated, p<0.001). Furthermore, during preventive treatment, rapamycin increased the levels of KLF2 transcript in CD44low CD62Lhigh naive T cell  (2,1 ±0,14 vs. 1,05 ±0,09, treated vs. untreated,p<0.05) and in CD62Llow CD44high activated T cell (1,02 ± 0,18 vs. 0,44 ± 0,08, treated vs. untreated, p<0.05).

Conclusion: Rapamycin is an effective treatment for EAM, resulting in a decrease in effector T cells, an increase in regulatory T cells, and upregulation of KFL2 in naive and activated T cells. Those observations suggest that rapamycin may represent an effective new therapeutic approach in patients with polymyositis. This approach may also be beneficial, since a deficiency in regulatory T cells has been reported during polymyositis.


Disclosure:

N. Prevel,
None;

Y. Allenbach,
None;

D. Klatzman,
None;

B. Salomon,
None;

O. Benveniste,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/beneficial-role-of-rapamycin-in-experimental-autoimmune-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology